At the recent ESMO (European Society of Medical Oncology) conference it was fantastic to see the number of folk who have iPhones and iPads. If they needed a laptop it was nearly always a Macbook Air.
Nearly 16500 delegates under one roof, everyone with a device to get onto the Internet and they crashed the Net server a few times.
The power of group computing.
Saturday, 6 October 2012
Herceptin duration
A few years ago when Herceptin (trastuzumab) was launched for the early stage of Her2+ breast cancer, the timing of treatment was fixed at one year. Why one year? No clue. Just a consensus figure decided by the oncology investigators.
At the European Oncology meeting held in the end of Sep 2012 - data from large studies were presented. The two main studies were comparing one year versus six months of Herceptin - this showed that probably one year is better than six months. The other study of one year versus two years showed that one is probably enough.
So the consensus a few years ago, was right. Twelve months is the magic figure (for now).
At the European Oncology meeting held in the end of Sep 2012 - data from large studies were presented. The two main studies were comparing one year versus six months of Herceptin - this showed that probably one year is better than six months. The other study of one year versus two years showed that one is probably enough.
So the consensus a few years ago, was right. Twelve months is the magic figure (for now).
Subscribe to:
Posts (Atom)